PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-233.51%
Negative net income growth while VET stands at 49.73%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
No Data
No Data available this quarter, please select a different quarter.
370.00%
Lower deferred tax growth vs. VET's 7308.71%, implying fewer future tax liabilities. David Dodd would confirm there’s no short-term tax shock instead.
46.67%
SBC growth well above VET's 65.94%. Michael Burry would flag major dilution risk vs. competitor’s approach.
-161.00%
Negative yoy working capital usage while VET is 501.82%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-161.00%
Negative yoy usage while VET is 501.82%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-10.81%
Both negative yoy, with VET at -2257.16%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-50.59%
Negative yoy CFO while VET is 11.86%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-11.86%
Both yoy lines negative, with VET at -4.77%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
41.18%
Acquisition growth of 41.18% while VET is zero at 0.00%. Bruce Berkowitz sees a mild outflow that must deliver synergy to justify the difference.
11.86%
Purchases growth of 11.86% while VET is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
16.07%
Liquidation growth of 16.07% while VET is zero at 0.00%. Bruce Berkowitz sees a mild difference in monetizing portfolio items that must be justified by market valuations.
-10.17%
Both yoy lines negative, with VET at -209.56%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-6.51%
Both yoy lines negative, with VET at -127.07%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.